NEWS: 公告在東京證券交易所JASDAQ標準市場新上市



Inhaled CNS Therapeutics

出版商 Greystone Research Associates 商品編碼 996041
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
吸入中樞神經系統(CNS)治療 Inhaled CNS Therapeutics
出版日期: 2021年03月17日內容資訊: 英文





  • 藥品投放市場動態
  • 自我管理趨勢
  • 中樞神經系統(CNS)治療:市場動態
  • 擴大家庭醫療服務
  • 市場驅動力
  • 吸入藥物的發展因素
  • 吸收
  • 生物利用度
  • 設備設計參數
  • 鼻用藥物的動力學
  • 鼻吸入器的特點
  • 跨肺藥物的動力學
  • 氣管吸引器的特徵
  • 吸入中樞神經系統治療:FDA批准的產品
  • 吸入抑鬱症藥物
  • 垂體激素吸入藥
  • 偏頭痛吸入藥
  • 吸入藥物治療疼痛
  • 帕金森氏病的吸入藥物
  • 精神分裂症的吸入藥物
  • 吸入性癲癇藥
  • 臨床試驗中的藥物
  • 臨床試驗中吸入的抑鬱症藥物
  • 臨床試驗期間吸入的偏頭痛藥物
  • 臨床試驗中吸入的中風藥物
  • 吸入的中樞神經系統療法:按細分市場分析
  • 阿爾茨海默氏病/癡呆
  • 抑鬱
  • 失眠
  • 偏頭痛
  • 疼痛管理
  • 帕金森氏病
  • 精神分裂症
  • 癲癇發作
  • 市場因素
  • FDA(美國食品和藥物管理局)法規
  • 臨床試驗
  • 藥物與醫療設備之間的合作
  • 從處方藥(Rx)轉換為非處方藥(OTC)
  • 仿製藥的影響


Product Code: JCT383F

Quick Onset and Ease of Use Driving Inhaled CNS Therapeutics

Delivering drugs to the central nervous system presents unique challenges. But drug developers and researchers have discovered that delivering CNS therapeutic drugs via inhalation mitigates several of these issues. The accessibility and vascular structure of the nose make it an attractive route for delivering both small molecule drugs and biologics across the blood-brain barrier to the CNS. Pulmonary delivery to the deep lung can have favorable pharmacokinetics. And inhaled delivery offers the potential for faster onset of action and less frequent dosing relative to oral drugs. These potential advantages have spurred activity in inhaled CNS therapeutics for a range of disorders. As aging population demographics and managed care initiatives drive growth in home health care and self-administration of drug therapies, inhaled medicine is increasingly being viewed as patient-friendly and cost-effective. Our analysis indicates that inhaled CNS administration is well positioned to take advantage of these trends and evolve into a significant factor in the future of pharmaceutical development and commercialization of CNS therapeutic drugs.

What You Will Learn:

  • Analyzes and evaluates systemic inhaled drug therapeutics for CNS disorders and diseases and assesses the market potential for existing and probable future products
  • Evaluates drug technologies and market development issues
  • Provides detailed assessments of CNS therapeutic market segments, market demographics, and business strategies
  • Charts product sales data, market share, and forecasts to 2012
  • Profiles sector companies, their product development activities, business strategies, and corporate alliances and affiliations
  • Assesses the importance of alliances and partnerships on future CNS therapeutic products
  • Evaluates the impact of economic, technology, and regulatory factors on Inhaled CNS Therapeutics

Table of Contents

Executive Summary

  • Drug Delivery Market Dynamics
  • The Trend toward Self-Administration
  • CNS Therapeutic Market Dynamics
  • Growth in Home Healthcare
  • Market Drivers
  • Inhaled Drug Development Factors
  • Absorption
  • Bioavailability
  • Device Design Parameters
  • Nasal Delivery Pharmacokinetics
  • Nasal Device Characteristics
  • Pulmonary Delivery Pharmacokinetics
  • Pulmonary Device Characteristics
  • Inhaled CNS Drugs: FDA-Approve Products
  • Inhaled Drugs for Depression
  • Inhaled Drugs for Pituitary Hormones
  • Inhaled Drugs for Migraine
  • Inhaled Drugs for Pain Management
  • Inhaled Drugs for Parkinson's Disease
  • Inhaled Drugs for Schizophrenia
  • Inhaled Drugs for Seizures
  • Development-Stage Drugs
  • Inhaled Drugs in Development for Depression
  • Inhaled Drugs in Development for Epileptic Seizures
  • Inhaled Drugs in Development for Migraine
  • Inhaled Drugs in Development for Stroke
  • Inhaled CNS Market Segment Analysis
  • Alzheimer's and Dementia
  • Depression
  • Insomnia
  • Migraine
  • Pain Management
  • Parkinson's Disease
  • Schizophrenia
  • Seizures
  • Market Factors
  • FDA Regulations
  • Clinical Trials
  • Drug-Device Collaborations
  • Rx-to-OTC Switching
  • Impact of Generics

Company Profiles